Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUIDIL vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Hypertension,Edema associated with congestive heart failure,Edema associated with renal disease,Edema associated with hepatic cirrhosis
Relief of moderate to moderately severe pain
5 mg orally once daily.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life: 1.5-2 hours (prolonged in hepatic impairment to 4-6 hours).
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Fluidil is extensively metabolized in the liver, primarily via glucuronidation and sulfation; cytochrome P450 enzymes play a minor role.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: 60-70% unchanged; biliary/fecal: <5%; hepatic metabolism: 25-35%.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
85-92% bound to albumin, alpha-1-acid glycoprotein.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg (extensive tissue distribution).
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: 60-80% (first-pass metabolism).
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg once daily. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not established for pediatric patients <18 years.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
No specific adjustment; use caution due to increased sensitivity.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
No FDA black box warning has been issued for Fluidil.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia),Hypovolemia and hypotension,Hyperuricemia and gout,Azotemia and renal impairment,Sulfonamide allergy cross-reactivity
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Anuria,Hypersensitivity to Fluidil or other sulfonamide-derived drugs,Hepatic coma or pre-coma,Severe electrolyte depletion
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid high-potassium foods (e.g., bananas, oranges, avocados, spinach, potatoes, salt substitutes with potassium chloride). Limit alcohol intake as it may worsen dizziness and dehydration. Grapefruit juice has not been reported to interact significantly, but caution is advised with other drugs. Maintain adequate fluid intake to prevent dehydration.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and third trimesters: May cause oligohydramnios due to diminished fetal renal function; use may lead to fetal renal impairment, persistent ductus arteriosus, and craniofacial abnormalities.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Excreted in human milk; M/P ratio not established. Use is not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
FLUIDIL is not indicated for use in pregnancy. No dosage adjustment recommendations are available for pregnant women; avoidance is mandatory.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Fluidil (a diuretic combination, e.g., hydrochlorothiazide and triamterene) may cause electrolyte disturbances; monitor potassium levels closely due to triamterene's potassium-sparing effect. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or hyperkalemia. Onset of diuresis occurs within 2 hours, peak effect at 4-6 hours. Administer in the morning to prevent nocturia.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take this medication in the morning to reduce nighttime urination.,Avoid potassium supplements or high-potassium foods (e.g., bananas, oranges, salt substitutes) unless directed by your doctor.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Stay hydrated but avoid excessive fluid intake; drink water as needed.,Report any rash, difficulty breathing, or swelling of the face/lips immediately.,Do not drive or operate machinery if you feel dizzy or lightheaded, especially during the first few days of treatment.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUIDIL vs ANEXSIA, answered by our medical review team.
FLUIDIL is a Mineralocorticoid that works by Fluidil is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUIDIL and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUIDIL is: 5 mg orally once daily.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUIDIL and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUIDIL is classified as Category C. FLUIDIL is contraindicated in pregnancy. First trimester: Associated with increased risk of major malformations, including neural tube defects and cardiac anomalies. Second and thi. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.